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Treating individual patients on the basis of specific factors, such as biomarkers, molecular
signatures, phenotypes, environment, and lifestyle is what differentiates the precision
medicine initiative from standard treatment regimens. Although precision medicine can
be applied to almost any branch of medicine, it is perhaps most easily applied to the field
of oncology. Cancer is a heterogeneous disease, meaning that even though patients may
be histologically diagnosed with the same cancer type, their tumors may have different
molecular characteristics, genetic mutations or tumor microenvironments that can
influence prognosis or treatment response. In this review, we describe what methods are
currently available to clinicians that allow them to monitor key tumor microenvironmental
parameters in a way that could be used to achieve precision medicine for cancer
patients. We further describe exciting novel research involving the use of implantable
medical devices for precision medicine, including those developed for mapping tumor
microenvironment parameters (e.g., O2, pH, and cancer biomarkers), delivering local
drug treatments, assessing treatment responses, and monitoring for recurrence and
metastasis. Although these research studies have predominantly focused on and were
tailored to humans, the results and concepts are equally applicable to veterinary patients.
While veterinary clinical studies that have adopted a precision medicine approach
are still in their infancy, there have been some exciting success stories. These have
included the development of a receptor tyrosine kinase inhibitor for canine mast cell
tumors and the production of a PCR assay to monitor the chemotherapeutic response
of canine high-grade B-cell lymphomas. Although precision medicine is an exciting
area of research, it currently has failed to gain significant translation into human and
veterinary healthcare practices. In order to begin to address this issue, there is increasing
awareness that cross-disciplinary approaches involving human and veterinary clinicians,
engineers and chemists may be needed to help advance precision medicine toward its
full integration into human and veterinary clinical practices.
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INTRODUCTION
Precision or personalized medicine endeavors to enhance patient
outcomes by treating individuals based on certain factors. These
factors can include disease biomarkers and molecular signatures
at the cellular level but also the phenotype, environment, and
lifestyle of the individual (1). While precision and personalized
medicine are similar concepts, there are some differences in
their definitions. Precision medicine greatly depends on data
collection, data analysis and information whereas personalized
medicine is a healthcare model that takes into account patient
genetics with consideration of patient preferences, beliefs,
attitudes, and social background. However, as a result of concerns
that the phrase “personalized” might be misinterpreted, possibly
leading patients to believe that unique treatments and/or drugs
were being developed particularly for themselves, “personalized
medicine” has now largely been replaced with the term “precision
medicine” (2, 3).
The National Research Council in America (4) adopted the
definition of precision medicine from the President’s Council of
Advisors on Science and Technology in 2008 as: “The tailoring
of medical treatment to the individual characteristics of each
patient. . . to classify individuals into subpopulations that differ in
their susceptibility to a particular disease or their response to a
specific treatment. Preventative or therapeutic interventions can
then be concentrated on those who will benefit, sparing expense
and side effects for those who will not.” As the definition implies,
the overall aim of precision medicine is to provide the most
effective treatment for a patient (5), enhancing the quality of care
whilst also decreasing the use of unnecessary diagnostic tests and
therapies, thereby reducing costs and side effects (6).
The Precision Medicine Initiative
Precision medicine has obtained increased awareness in recent
years within both human and veterinary research and clinical
communities. The announcement of the “Precision Medicine
Initiative” by Barack Obama during the State of the Union
Address in 2015 led to increased media coverage and awareness
within the lay community. This initiative sought to encourage
research in the field of precision medicine in an effort “to bring
us closer to curing diseases like cancer and diabetes—and to give
us all access to the personalized information we need to keep
ourselves and our families healthier” (7). The Precision Medicine
Initiative, now termed “All of US,” plans to register over 1 million
participants (8). Those enrolled are expected to disclose any
data produced from sequencing, digital healthcare technologies
and electronic medical records over a 10 year period. These
data will then be examined to increase our understanding of
disease biology and pathogenesis whilst providing data to enable
a precision-led healthcare approach for both individuals and the
population as a whole.
The former Prime Minister of the UK, David Cameron,
launched the 100,000 Genomes Project in 2012 (9). This project
was led by Genomics England and the National Health Service
and aimed to use whole-genome sequencing to improve the
management of patients diagnosed with cancer and rare inherited
diseases. 13 Genomic Medicine Centers were created to carry
out this programme and in 2018 this initiative reached its goal
of sequencing 100,000 whole genomes. This project not only
provided whole-genome sequencing data for patient treatment
selection or enrolment into clinical trials, but also enabled
researchers to have access to anonymous clinical and genomic
data sets. In veterinary medicine in the UK, “Dogslife” was
the first national longitudinal canine health program to be
set up. Launched in 2010, the study aims to identify genetic
and environmental risk factors for canine diseases and use the
information to generate disease risk reduction approaches (10).
The feasibility of implementing the precision medicine
initiative has improved in recent years largely due to decreased
costs associated with high-throughput DNA sequencing, the
implementation of electronic medical records across the country
and the utilization of advanced imaging systems that have
the ability to assess the tumor microenvironment (TME).
Additional genome-based technologies are also progressively
being employed as either diagnostic assays to categorize disease,
or as prognostic or predictive tests. Collectively, these approaches
have been seen as the foundation for a new molecular disease
classification system which will deliver a more accurate means
by which clinicians can screen for and discover disease at
its earliest stages. This ultimately will enable the selection of
drugs and/or treatments directed by individual patient genetics.
Since disease evolution from baseline risk to clinical symptoms
frequently takes many years, intermittent molecular and digital
profiling is expected to advance healthcare approaches from acute
intervention and disease control toward a greater emphasis on
pro-active management of disease risks and eventually disease
prevention (8).
Oncology is perhaps one field that precision medicine can be
most readily applied to. Cancer is a heterogeneous disease and
although patients may be diagnosed with the same histological
cancer type, their tumors may have varying genetic mutations or
TMEs that lead to different responses between patients treated in
the same way (11). Distinct treatment approaches for individual
patients may therefore lead to improved outcomes (12). Within
the field of oncology there is increasing awareness that
cross-disciplinary approaches involving human and veterinary
clinicians, engineers, and chemists may be needed to make
significant progress in the field of precision medicine. In this
review we discuss precision medicine with particular emphasis
on the TME and describe how multidisciplinary groups are
investigating the use of novel implantable technologies to achieve
precision medicine. Finally, we describe a range of veterinary
clinical studies that have used a precision medicine approach in
a range of cancers in an attempt to improve patient outcome
(Figure 1).
The Tumor Microenvironment
Assessing the TME to improve patient treatment can be
considered an important aspect of precision medicine. Stephen
Paget initially put forward the concept of the TME in his
seed and soil theory, which postulated that cancer development
and progression are regulated by the interaction of cancer
cells with the external environment of the tumor (13). The
TME is a complicated network, comprising of not only the
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FIGURE 1 | Comparison of the currently employed traditional healthcare practices with prospective precision medicine approaches in veterinary oncology. Veterinary
patients presenting with the same tumor type are currently classified by their clinical stage and histological grade. This usually leads to a dichotomic decision to treat
with standard specific treatment protocols, or not to treat at all. The vision of precision medicine is to develop diagnostic and monitoring techniques, applied to tumors
of the same histological grade and clinical stage, to distinguish an optimized treatment strategy for each individual patient. Figure created with BioRender.com.
tumor cells themselves but also various tumor-associated cells.
These associated cells include cancer stem cells, cancer-associated
fibroblasts, mesenchymal stem cells, pluripotent stromal cells,
cancer-associated adipocytes, endothelial cells, pericytes, and
tumor-associated immune and inflammatory cells. These tumor-
associated cells secrete soluble molecules and microvesicles that
control the interactions of cancer cells with other cell types. This
can influence how the tumor cells proliferate, oppose apoptosis,
avoid elimination from the immune system, preserve stemness,
invade, and metastasize (14).
The physiology of cancers differs greatly from that of normal
tissues within the body; this situation results from the tumor
needing to develop its own blood supply as it begins to outgrow
the accessible vasculature from the organ in which it originates.
However, the tumor neovasculature is crude and disordered,
suffering from many functional and structural irregularities.
This tumor vasculature system is therefore unable to satisfy
the metabolic needs of the developing cancer (15). This leads
to areas within a tumor that have differing O2 tensions
(anoxia, hypoxia, and normoxia) in combination with glucose
deprivation, interstitial hypertension, and extra-cellular acidosis
(16, 17). The differing compositions of TME between patients is
thought to impact the effectiveness of different cancer therapies.
If TME parameters such as biomarkers, cancer metabolites,
chemotherapeutic drug concentrations or intra-tumoural pH
and O2 could be analyzed over the course of a patient’s
treatment schedule, then this information could influence the
management of the patient. Treatment could be tailored on
the basis of the tumor’s response to the initial therapy or
through the identification of early markers of tumor recurrence
or metastasis (18).
Tumor Hypoxia and pH
Low O2 levels, or hypoxia, is a regular feature of many tumors.
Approximately 60% of solid cancers contain hypoxic areas
heterogeneously dispersed throughout the tumor (15); this makes
O2 a very relevant TME parameter to investigate. The vast
majority of non-cancerous mammalian tissues operate in O2
levels of 2–9%. Hypoxic and severely hypoxic states, defined as
≤2% O2 and ≤0.02% O2, respectively (19), can occur within
tumors via 4 main mechanisms:
1) Diffusion-limited hypoxia. Mainly leading to chronic hypoxia,
diffusion-limited hypoxia is caused by viable aerobic cancer
cells positioned close to blood vessels using the O2 transported
in red blood cells (RBC). O2 levels decrease as the distance
from the vasculature increases, resulting in hypoxia (20, 21).
Even though O2 can diffuse up to 150–180µm from a blood
vessel, the distance at which hypoxia arises is dependent on the
ability of RBC to carry O2, in addition to the metabolic needs
of the cancer cells situated closest to the blood vessels (22).
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2) Perfusion-limited hypoxia. This mostly leads to acute and
transient hypoxia, and is caused by interruptions to blood
flow (23, 24) resulting from structural/functional defects of
micro-vessels within a cancer, which can lead to micro-vessel
collapse/blockade (25). This may lead to complete ischemic
hypoxia, or hypoxia that stops RBC flow but permits plasma
flow to continue the provision of nutrients to the cancer cells.
3) Anemic hypoxia. Resulting from therapy-induced and/or
tumor-associated anemia that causes decreased RBC O2
transport capabilities (20, 26).
4) Macroscopic regional hypoxia. Occurs due to the production
of an O2 gradient over the length of a blood vessel. Blood
present at the arterial extremity has the highest O2 levels,
which is quickly consumed by tumor cells present in this area.
O2 levels in the blood decrease as distance from the arterial
end increases. As a result, cancer cells positioned at the distal
end of the blood vessel may be hypoxic, even if they are close
to the vessel (27, 28).
While it seems reasonable that low O2 levels would produce
an adverse environment for cells to survive, tumor cells possess
the ability to create a hypoxic response through alterations in
gene expression that shield them from cell death mechanisms
(29). Cancer cells that are incapable of adjusting to low O2
concentrations will perish, resulting in the selection of tumor
cells with hypoxic-induced, genetically-fixed characteristics,
known as a “hypoxic phenotype” (30). This hypoxia-driven
malignant progression can lead to tumor cells becoming
increasingly metastatic and therapy-resistant (31). There are a
variety of crucial inducible transcription factors that participate
in this hypoxic response, with hypoxia inducible factor-1 (HIF-
1) being the one that has been most comprehensively studied
so far (32–35). In areas where O2 levels are approximately 2%
or less, these transcription factors are stabilized and transported
to the cell nucleus, where they then bind hypoxia-response
elements present in the promoter regions of target genes,
leading to transcription (36). These hypoxia-regulated genes
are involved in processes such as erythropoiesis, angiogenesis,
apoptosis, autophagy, proliferation, glucose metabolism, intra-
cellular acidosis, and metastasis. These adaptations enhance the
capacity of cancer cells to endure these hostile low O2 TME
regions (37).
In order to counteract the reduced mitochondrial ATP
production that occurs due to low O2 levels, hypoxic cells
can instead get their energy through anaerobic glycolysis,
resulting in the generation of lactic acid, which can cause
substantial acidosis within solid cancers (38). Even in normoxic
conditions, some cancer cells still rely on glycolysis for energy
production. This phenomenon, known as the Warburg effect,
can lead to discrepancies in the spatial/temporal distribution
of areas with low O2 concentrations and increased amounts of
acidosis (39–41).
The Tumor Microenvironment and Its Effect on
Treatment Responses
The heterogeneity that occurs within the TME can influence how
tumors respond to frequently-employed cancer treatments and
can subsequently have a negative impact on patient outcome. The
abnormal cancer vasculature can inhibit the delivery of systemic
drugs to the tumor, leading to heterogeneous drug dissemination
within cancer tissue (42). In immunotherapy, high molecular
weight drugs access cancer cells by the interstitial space rather
than through blood vessels (43). Interstitial hypertension that can
occur within tumors pushes fluid out of the interstitial space, thus
restricting drug delivery (44, 45).
O2 levels within tissues can also affect tumor radiosensitivity
and the efficacy of chemotherapeutic drugs (46). Radiotherapy
works through damaging the DNA of cancer cells, either via
the direct route (the ionizing radiation directly produces double
or single strand breaks in the DNA) or the indirect route
(ionizing radiation produces free radicals within the cancer
cells, which subsequently cause DNA damage). It has been
shown that tumor cells exposed to low O2 concentrations
can tolerate radiation doses 2–3 times higher than that which
can be withstood by normoxic cancer cells. The O2 fixation
hypothesis has been suggested to explain the role of O2 in
radiotherapy (19, 47). O2 present in cancer tissues reacts with
DNA radicals produced as a result of radiation treatment, leading
to the production of irreparable peroxy radicals. However, this
reaction does not take place when O2 is not present; in these
instances, damaged DNA strands can be repaired by free-radical
scavengers such as endogenous thiols, granting these hypoxic
cancer cells a considerable survival advantage (48). The effect
that O2 has on radiotherapy was emphasized in a significant
global clinical study which showed that pre-treatment O2 levels
within head and neck tumors was a prognostic factor for survival
post-radiotherapy (+/– chemotherapy, surgical intervention, or
radiosensitizer) (49). While the form of hypoxia (i.e., acute or
chronic) is unrelated to the initial radioprotective effect, cancer
cells under chronic hypoxic conditions are usually more deprived
of nutrients in comparison to acutely hypoxic cells. This nutrient
deprivation could have a part to play in the cell’s capacity to repair
radiation-induced DNA damage; as such, acute hypoxic cancer
cells may be more radioresistant than chronic hypoxic cells.
Reduced O2 levels and low pH conditions can also decrease
the proliferation rates of tumor cells (50); this can in turn inhibit
the efficacy of cytotoxic drugs that target rapidly-dividing cancer
cells (51). Chemotherapeutic drugs such as doxorubicin (DOX)
have also been shown to have increased efficacy in normoxic
conditions; the intra-cellular metabolite of DOX reacts with O2
present in the TME, leading to the generation of reactive oxygen
species (ROS). These ROS damage major components of the cell,
leading to cellular death (52). This reaction does not take place in
areas of the tumor where O2 levels are reduced (≤0.33%), leading
to a reduction in the efficacy of DOX (53–55).
Therapeutic Strategies to Target Hypoxic
Tumors
Different treatment approaches have been assessed for
their capacity to surmount hypoxia-related resistance to
radiation. These strategies include hyperbaric O2 treatment,
the administration of agents that target the hypoxic areas of
cancers, or drugs that are activated in these low O2 regions.
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Hyperbaric O2 therapy, which uses high ambient air pressures
to increase the amount of O2 carried in the patient’s blood,
has been found to have a beneficial effect in patients suffering
from head and neck squamous cell carcinomas (HNSCC) (56);
in spite of this, varying data produced from clinical trials in
other cancer types, in addition to the logistical issues associated
with its use, have hindered its general utility. Additionally,
this form of therapy is not appropriate in combination with
some chemotherapeutic drugs, including DOX, because it
increases the likelihood of systemic ROS-mediated toxicities
(57). A different method that has been used to increase O2
levels within tumors is the administration of carbogen with
nicotinamide. Carbogen (also named Meduna’s Mixture after
its inventor) is a mixture of CO2 and O2 and has the ability
to diminish diffusion-limited hypoxia, while nicotinamide is a
vasoactive agent that counteracts acute hypoxia resulting from
reduced perfusion. Accelerated radiotherapy in combination
with carbogen and nicotinamide (ARCON) has been assessed
in several clinical trials, demonstrating enhanced locoregional
control and disease-free survival (58, 59). Likewise, clinical
trials using nitroimidazole derivatives (e.g., nimorazole and
doranidazole) that mimic the effects of O2, have shown that
these drugs can produce survival benefits when combined with
chemoradiotherapy in HNSCC (60) and non-small cell lung
cancer (NSCLC) patients (61), or when used with radiotherapy
alone (62, 63). In both Norway and Denmark, nimorazole
combined with radiotherapy is the standard of care treatment for
head and neck cancers (60, 62, 64). Additionally, the combination
of radiotherapy with nicotinamide and carbogen has exhibited
encouraging results in bladder and laryngeal cancers (65).
The identification of hypoxic tumor areas can also allow
more effective delivery of radiation. Tumors that have large
regions of hypoxia could be given increased radiation doses
over the gross tumor volume; however, this method may lead
to an escalated risk of damaging surrounding normal tissues.
A superior technique would be to establish a biological target
volume based on low O2 levels. With this approach the overall
dose given to the gross tumor volume stays the same but it
is redistributed to specific tumor regions; increasing the dose
delivered to the low O2 areas, whilst decreasing that given
to the regions with higher O2 concentrations. The biological
target volume could also be given boost doses, either applied
homogeneously over the hypoxic sub-volume, or altered in
accordance with the local O2 levels. Improvements in radiation-
delivery technology, including intensity-modulated and image-
guided radiotherapy, enable highly conformal and accurate
delivery of radiation; these developments mean that the use
of sculpturing techniques or dose painting by numbers are
becoming increasingly attainable (66). These new treatments are
substantiated by modeling studies, which indicate that a boost
dose of 10Gy to low O2 regions in HNSCC patients could lead
to a 17% increase in tumor control probability, without escalating
the risk of complications (67). A different study has demonstrated
that dose escalation, employing dose painting by numbers to the
biological target volume, could also result in improved tumor
control probability compared to that achieved with uniform dose
escalation (68).
Case selection is a crucial feature of clinical trials designed
to assess hypoxia-modifying therapies. Unfortunately, many
previous studies enrolled patients into these clinical trials without
initially determining the hypoxic nature of the tumors. Failure
to specifically detect hypoxic tumors would inevitably lead to
treating patients who were unlikely to gain any benefit from
hypoxic modification. This issue leaves us with a crucial question:
what is the best method to analyse O2 levels so clinicians can
effectively decide which patients will benefit from therapeutic
strategies designed to target hypoxic cancer cells?
Tumor Functional Assessment
There are various methods by which hypoxic areas within
tumors can be detected, but none are used routinely either due
to their invasive nature or difficulties in incorporating them
into clinical practice (Table 1). One of the first approaches for
directly measuring intra-tumoral O2 was with the Eppendorf
O2 electrode (70). This technique showed associations between
hypoxia and treatment responses in numerous cancer types (71–
73, 73–75) and that O2 concentrations within breast cancer tissue
can be lower than that of normal breast tissue (70). However,
this technique is invasive and only applicable to readily accessible
tumors and is not used routinely in the clinic.
While the Eppendorf O2 electrode represents a direct method
of measuring O2 concentrations within cancer tissues, there are
also various indirect methods that can be utilized. The use of
cancer tissue biopsies to identify molecular reporters of O2 is
one such indirect method. Nitroimidazole-based agents, such as
pimonidazole, are chemicals that produce adducts with intra-
cellular macromolecules in reduced O2 concentrations (76);
pimonidazole has been utilized successfully in clinical trials
to choose patients that would be suited for treatment with
hypoxia-modifying drugs alongside accelerated radiotherapy
(58, 59). To exploit the cellular response of cancer cells to
low O2 levels, the expression levels of hypoxia-induced genes,
mRNAs, and proteins have also been employed as biomarkers of
hypoxia (77–80). In dogs with mammary tumors, high VEGFA
gene expression has been associated with poor outcome, with
one study suggesting that it could be used as a prognostic
marker to identify dogs at risk of disease progression (81).
However, markers including HIF-1, CA9, VEGF and GLUT1,
analyzed either at the mRNA or protein level, or through
the use of nitroimidazole, have frequently brought about
contradictory results. This is probably because these genes and
proteins can be regulated by factors other than O2, such as
glucose levels or extracellular pH (82–84), or their expression
is induced at O2 concentrations not low enough to have a
significant radiobiological effect. For nitroimidazole to bind to
macromolecules it requires cells to be hypoxic for long periods
of time. Therefore, this can result in an underestimation of the
levels of acute hypoxia within the TME.
These problems led to the production of hypoxic signatures
that were created by pinpointing a variety of genes that
were upregulated in low O2 conditions; these signatures were
produced from either cell lines or clinical tissues (85–92).
The Toustrup15-gene-classifier is one such signature that was
generated from a panel of genes ascertained using HNSCC cell
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TABLE 1 | Methods used for measuring tumor hypoxia.
Microelectrode
Technique: O2 electrodes are put into solid tumors
Benefits: Provides direct readings of O2 levels. Simple to use. Ability to acquire real-time readings
Drawbacks: Invasive procedure. May only be utilized in tumors that are accessible. Incapable of differentiating viable hypoxic tumor regions from
necrotic areas
Tissue based biomarkers
Technique: Nitroimidazole compounds, such as pimonidazole, are given systemically and are changed into protein adducts in hypoxic cells. Detectable
in biopsies through IHC
Benefits: Provides an estimate of hypoxia heterogeneity in different cancer regions
Drawbacks: Indirect measurement of O2 concentrations. Invasive procedure (biopsy required). May not distinguish intermediate hypoxic phenotypes
(HIF-1 stabilization occurs at higher O2 levels than that at which adducts are formed). Real-time measurements are not possible
Tissue based biomarkers
Technique: Assessing the expression of proteins induced in hypoxic conditions (GLUT1, CA9)
Benefits: The location of protein expression and data on functional status can be provided through IHC. Gives an estimate of hypoxia heterogeneity
within different cancer regions
Drawbacks: Indirect measurement of O2 concentrations. Invasive procedure (biopsy required). Protein expression can be manipulated by factors other
than hypoxia. Method limited to a small number of biomarkers due to antibody sensitivity and specificity issues. Real-time measurements are not possible
Tissue based biomarkers
Technique: Assessing gene expression levels
Benefits: Prognostic/predictive of response to hypoxic radiosensitizers
Drawbacks: Indirect measurement of O2 concentrations. Invasive procedure (biopsy required). Gene expression can be manipulated by factors other
than hypoxia. Real-time measurements are not possible
Serological based biomarkers
Technique: Analysis of biomarkers present within the serum (osteopontin)
Benefits: Non-invasive. Real-time measurements are possible
Drawbacks: Indirect measurement of O2 concentrations. Biomarker levels can be manipulated by factors other than hypoxia. No information provided
on hypoxic heterogeneity in different cancer regions.
Positron emission tomography
Technique: Copper-complexed dithiosemicarbazone or nitroimidazole agents, given systemically, are taken up by hypoxic cancer cells. Agents are
attached to radiotracers that can be distinguished through PET imaging
Benefits: Non-invasive procedure. Capable of acquiring real-time data. Can provide an estimation of hypoxic heterogeneity in different cancer regions
Drawbacks: Indirect measurement of O2 concentrations. May not distinguish intermediate hypoxic phenotypes (HIF-1 stabilization occurs at higher O2
levels than that at which agents form adducts). Safety issues with the use of radioisotopes
Magnetic resonance imaging
Technique: Either blood oxygen level-dependent (BOLD) imaging, dynamic contrast-enhanced MRI (DCE-MRI) or oxygen-enhanced MRI (OE-MRI)
Benefits: Non-invasive procedure. Real-time measurements can be obtained. Can provide an estimation of hypoxic heterogeneity in different cancer
regions. Radiation exposure avoided
Drawbacks: Possibility of artifacts. The parameters used to reflect O2 levels and their link with hypoxia is yet to be determined
Advantages and disadvantages of each method used to measure tumor hypoxia (69).
lines; these genes were found to be upregulated by hypoxia,
independent of pH (85). This gene signature was further
developed in a training cohort of 58 patients suffering from
HNSCC, with O2 levels analyzed with an electrode. The
classifier was validated in a Danish study where patients were
randomly selected to be treated with radiotherapy combined
with either the hypoxic radiosensitizer nimorazole or a placebo.
The classifier was shown to be prognostic and also possessed
predictive power for hypoxic modification (85, 93, 94). The
26-gene signature generated by Eustace et al. (91) is another
classifier based on a metagene signature generated from patients
suffering from lung, breast and head and neck cancers. The
ARCON trial carried out in the Netherlands assessed this
signature, evaluating radiotherapy combined with nicotinamide
and carbogen compared to radiotherapy alone in patients with
laryngeal cancer. The patients that were classed as “more
hypoxic” with the 26-gene signature exhibited significantly
better locoregional control when treated with hypoxia-modifying
compounds (44, 59).
Indirect assessments of tumor hypoxia rely on the ability to
obtain a tissue sample. Unfortunately, these can be extremely
challenging or even impossible to acquire due to tumor location
or the patient’s condition. Treatment response monitoring
through repeat biopsies is also difficult to clinically justify. The
measuring of hypoxic-related biomarkers in blood samples has
been investigated as a means of overcoming these issues. In
humans, high levels of plasma osteopontin have been associated
with a poor prognosis in head and neck cancers, which could be
improved with O2-mimicking drugs (95). Serum concentrations
of HIF-1α and VEGF in dogs with mammary tumors have
also been shown to have prognostic merit; high VEGF levels
were associated with lymph node and distant metastasis, tumor
vascularization and decreased survival times, whereas high HIF-
1α levels were related to local recurrences or metastatic lesions
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(81). The major disadvantage of using blood to evaluate the
hypoxic status of tumors is that the sample, in effect, does not
analyse the tumor at all. This means that specific hypoxic tumor
areas cannot be identified and alterations to the O2 distribution
within the tumor cannot be assessed. Tumor hypoxia assessment
through non-invasive advanced imaging techniques, such as
positron emission tomography (PET) and magnetic resonance
imaging (MRI), offer the ability to evaluate the whole tumor
volume whilst providing a means for repeat measurement.
Dynamic contrast-enhanced MRI (DCE-MRI) typically uses
an intravenous injection of a gadolinium-based contrast agent.
Signal changes identified by MRI as the agent passes through
the tumor’s blood supply provide an indication of intra-tumoral
perfusion. Blood O2 level-dependent (BOLD) MRI imaging
detects signal alterations caused by changes in deoxygenated
hemoglobin levels. Patients are required to undergo dynamic
challenges to alter deoxygenated and oxygenated hemoglobin
ratios in order to map hypoxic tumor regions (69). Over
the years, PET imaging has been developed to assess specific
tumor characteristic such as glycolysis (2-deoxy-2-[18F]fluoro-D-
glucose [18F-FDG]), hypoxia ([18F]fluoromisonidazole [FMISO],
CA9, copper-complexed dithiosemicarbazone [64Cu-ATSM]),
and proliferation (3′-deoxy-3′-[18F]fluorothymidine [18F-FLT]).
18F-FDG, 64Cu-ATSM, and 18F-FLT have all shown promising
results for monitoring treatment responses in numerous human
and canine cancer types (96–100).
One canine study demonstrated the feasibility of using
multiple PET tracers to simultaneously evaluate glycolysis (18F-
FDG), hypoxia (64Cu-ATSM), and proliferation (18F-FLT) in
a dog diagnosed with a tibial fibrosarcoma. Serial imaging
performed before, during and after 10 fractions of 4.5Gy
demonstrated a heterogeneous spatial distribution of the 3
tracers. 64Cu-ATSM uptake progressively decreased during
and after radiotherapy, suggesting either tumor reoxygenation
(in areas where 18F-FDG uptake was maintained) or the
development of dead tumor tissue (in areas of reduced 18F-FDG
uptake). Although 18F-FDG and 18F-FLT uptake significantly
decreased following the completion of radiotherapy, fluctuations
were seen throughout the treatment course. 18F-FLT fluctuations
could be indicative of accelerated tumor cell repopulation,
whereas 18F-FDG fluctuations might suggest the presence of
inflammation or tissue remodeling. The authors put forward the
suggestion that each tracer provided distinct information about
the TME, including heterogeneity, phenotype and response to
treatment, which could be used to tailor therapies to individual
patients (101). Other canine studies have used 64Cu-ATSM and
18F-FDG to identify biological target volumes for dose painting
radiotherapy (102), with 18F-FLT and 18F-FDG also having been
investigated as a means of monitoring radiotherapy responses
and identifying disease progression (103). Pre-treatment 18F-
FDG, 18F-FLT, and 61Cu-ATSM scans could also be used to
predict the response to radiotherapy (104).
Unfortunately, these advanced imaging techniques are not
without limitations; in particular, the resolution (i.e., voxel size;
a 3D representation of a pixel as determined by slice thickness
and pixel size) offered by these techniques can be greater than the
hypoxic tumor areas themselves. This means that small hypoxic
“hotspots” may be classified as normoxic if the mean value for
the area falls below a specific cut-off point. In clinical terms, PET
imaging may not be able to accurately characterize intra-tumoral
hypoxic heterogeneity at microregional levels.
Currently, regardless of whether tumor hypoxia, glycolysis,
or proliferation are assessed using tissue or blood samples or
through advanced imaging, the results only provide a static
indication of the TME at the time of analysis. This is a
significant limitation of any technique, as the TME is a dynamic
landscape with potentially significant spatial and temporal
changes occurring throughout the tumor at any given time.
Therefore, despite technological advances, clinical techniques
that can acquire continuous real-time data in order to generate
an accurate 3D map of the TME, including its hypoxic status,
within the entire tumor volume are still not available. A potential
solution to this unmet clinical need is the use of an implantable
sensor designed to continually measure key TME parameters.
This technique has the potential to provide information on the
spatial and temporal changes that occur within the tumor during
a patient’s treatment course.
Implantable Technology and Cancer
Developments in the fields of electronics, mechanical
engineering, and microfabrication have resulted in increased
interest in the clinical applications of implantable medical
devices for precision medicine. In line with this, studies have
begun investigating whether implantable devices could be used
to map the TME for parameters such as O2, deliver local drug
treatments, assess treatment responses, and monitor for tumor
recurrence and metastasis (Figure 2).
Implantable Sensors and Monitoring of Tumor
Oxygenation and pH
Due to the limitations associated with current technologies
designed for measuring intra-tumoral O2 levels, researchers are
investigating novel ways to address this unmet clinical need. Two
recent studies have developed implantable sensors that are able to
provide O2 and pH measurements within a tumor.
The Implantable Microsystems for Personalized Anti-Cancer
Therapy (IMPACT) project is developing both miniaturized
Clark-type electrochemical O2 sensors, methylene blue-based
electrochemical pH sensors and ISFET pH sensors (105). The
purpose of the project is to manufacture implantable wireless
sensors for the real-time monitoring of intra-tumoral O2 levels
and pH, thus allowing radiotherapy to be delivered at the
most effective location and time. In vivo mouse xenograft
tumor studies using a human breast cancer cell line were
used to evaluate biofouling and the foreign body response
that occurred when constituent materials of the IMPACT
sensors were implanted into a solid tumor. This study was
the first to assess the effects of modern implantable materials
within a TME. The authors concluded that none of the
evaluated materials had any detrimental effect on tumor
growth or body weight of the murine host. Up to 14 days
post-implantation, immunohistochemistry (IHC) showed no
significant changes in hypoxic cell number, tumor necrosis,
apoptosis, proliferation, collagen deposition, or immune cell
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FIGURE 2 | Applications of implantable technologies for precision medicine. GTV, gross tumor volume; CTV, clinical tumor volume; PTV, planning target volume.
Figure created with BioRender.com.
infiltration. The authors suggested that the absence of biofouling
supports the use of these materials in medical devices
designed for implantation within solid tumors (106). Functional
O2 sensors were subsequently evaluated in a translational
large animal lung cancer model (107). Following CT-guided
implantation into lung tumors, initial results have demonstrated
that these sensors remained functional and were sufficiently
sensitive to monitor acute changes in oxygenation within tumor
tissue (108).
Other researchers have taken a different approach to
monitoring TME parameters. One such study has designed a
miniaturized implantable nuclear magnetic resonance (NMR)
sensor. This incorporates a responsive NMR contrast agent
that can be assessed wirelessly via magnetic coupling to an
external reader without the need of an MRI scanner. This study
demonstrated the feasibility of the implantable NMR sensor to
separately detect pH and O2 using in vitro and in vivo model
systems. The in vivo experiments consisted of monitoring intra-
tumoral pH in a xenograft mouse model and assessing O2 levels
in a rat hind limb constriction model. The authors suggested
that this sensor could be implanted at the time of tumor biopsy
and could remain within the tumor providing repeat O2 and pH
measurements from the same tumor area. They further suggested
that the sensor could be used for other NMR applications,
such as low-resolution spectroscopy to identify soluble
biomarkers (109).
Although further engineering development of both sensor
types is required, the results from these exciting pre-clinical
studies have shown that intra-tumoral O2 and pH can be
monitored in real-time. If they progress toward testing in clinical
trials, they could eventually prove to be formidable tools to
identify and target treatment-resistant tumor areas.
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Implantable Sensors and the Clinical Monitoring of
Cancer Progression
The ability to monitor treatment responses and identify early
indicators of tumor recurrence may be achieved through the use
of implantable medical devices. Sensors that detect cancer-related
biomarkers could be implanted either within the tumor at the
time of biopsy or within the tumor bed at the time of surgery
following tumor excision (110, 111). This application would
be highly useful in disease conditions where advanced imaging
cannot reliably distinguish between necrosis/fibrosis resulting
from previous surgery/chemotherapy/radiotherapy and tumor
recurrence (e.g., glioblastomas) (112).
The first in vivo report to support the use of implantable
devices for this application was designed to detect the β
subunit of human chorionic gonadotrophin (hcG-β) (111),
a soluble cancer-related biomarker known to be secreted in
high levels in ovarian and testicular cancers. The sensor
was designed using nanoparticle magnetic relaxation switches
(MRSw) conjugated with hcG-β antibodies and was evaluated
using a mouse xenograft model. Sensors were implanted into
tissue surrounding hcG-β-producing human choriocarcinoma
xenograft tumors (JEG-3). The results demonstrated that MRI
was able to identify MRSw aggregation that occurred with hcG-β
antibody binding, which provided evidence that the implanted
device could successfully detect hcG-β in peri-tumoral tissue.
The authors suggested that, as MRSw can be modified to detect
various molecules, they might provide a means of detecting and
monitoring a variety of cancer-related biomarkers (113).
Another study has investigated the use of implantable
devices designed to identify early indicators of metastasis
through the evaluation of localized immune responses. This
study developed a synthetic microporous polymer scaffold
that promotes tissue ingrowth through vascularization, cellular
infiltration, and immune cell recruitment. This engineered
microenvironment was shown to have characteristics of a
metastatic niche that could capture circulating tumor cells. In
vivo evaluation of the immune responses that developed within
subcutaneously-implanted scaffolds was performed using an
orthotopic breast cancer murine xenograft model. Phenotypes
and gene expression profiles of immune cells were determined
from sequential scaffold biopsies obtained up to 21 days post-
primary tumor inoculation. These results suggested that an
immunosuppressive microenvironment developed which had
characteristics of metastatic diseased lung. Following excision
of the orthotopic breast tumor, sequential analysis of immune
phenotypes within the scaffold showed an initial response to
surgery, which could differentiate mice that suffered a tumor
recurrence from those that survived. The authors concluded
that the microenvironment that developed within the scaffold
reflected the immunosuppressive events that contribute to the
development of metastatic disease. Furthermore, monitoring
these immune responses identified animals which had disease
progression from those that responded to surgery (114).
Technologies such as this may provide a means of identifying
patients at risk of developing metastatic disease or those who
have early metastatic disease that is clinically undetectable by
imaging. Patient outcomes have the potential to be improved
if the earliest stages of metastatic disease can be identified and
treatment intensification initiated.
Implantable devices can not only be designed to monitor
specific tumor-related factors but may be utilized to assess the
accuracy of delivering a desired radiation dose to a specific
tissue/tumor area, an issue which is fundamental to the clinical
effectiveness and success of radiotherapy. To address this,
implantable dosimeters have been developed to assess what
radiation dose has been delivered per treatment fraction to the
planned target volume. This dose-verification system has gained
FDA approval for use in prostate and breast cancers, and has the
potential to allow radiotherapy treatment regimens to become
optimized for individual patients (115).
Cancer Treatment and Implantable Technology
Although many cancer types can be treated with a variety
of clinically-approved drugs, clinicians are often faced with
the difficult decision of which drug would be most effective
in individual patients. Sometimes this decision can be made
based on published evidence, but occasionally the choice will
be empirical and based solely upon the clinician’s personal
experiences. To overcome this issue, studies have investigated
whether multiple drugs can be simultaneously evaluated in the
tumor itself to provide information on which is most effective.
These types of studies have the ability to account for tumor
heterogeneity, as drug effects can be analyzed within spatially
distinct TME regions.
One study developed a medical device that was able to
deliver 8 drugs concurrently into mapped and defined regions
within a tumor. This research initially used lymphoma and
NSCLC murine xenograft models for validation of the device.
Following intra-tumoral injection, drug distribution was assessed
through radiolabelling imaging. Tumors were excised up to
72 h after drug delivery and cytotoxic drug responses were
evaluated through IHC. Results demonstrated that not only could
local tumor responses predict response to systemically-delivered
drugs, but that the most effective compound for a chemoresistant
lymphoma xenograft tumor could be identified by screening
multiple drugs simultaneously. This work was followed by a
small clinical study designed to assess patient satisfaction and
procedural complications. Using the device, combined with
ultrasound guidance, human and canine lymphoma patients
received microinjections of vincristine into enlarged lymph
nodes. Results suggested that localized tumor responses can be
tested in a toxicity-sparing manner (116). Employing a similar
approach, a further study developed a short-term implantable
device composed of multiple reservoirs. Following intra-tumoral
implantation, each reservoir was capable of delivering drugs
into spatially distinct TME areas at concentrations equivalent to
systemically-achievable doses (117). 24 h after implantation, the
device and the immediately adjacent surrounding tumor tissue
was removed with IHC performed to assess each drugs’ cytotoxic
effect (117).
These studies demonstrate that implantable devices can be
used to conduct in vivo drug testing through local delivery
directly within the TME. The ability to evaluate spatially-defined
tumor responses to multiple drugs provides an opportunity
Frontiers in Veterinary Science | www.frontiersin.org 9 November 2020 | Volume 7 | Article 598338
Gray et al. Tumor Microenvironment and Precision Oncology
to identify a patient’s optimal drug treatment before definitive
systemic chemotherapy begins.
A further consideration for determining the most appropriate
chemotherapy regimen for a patient is the issue of multidrug
resistance (MDR). MDR occurs when cancer cells develop cross-
resistance to multiple functionally and structurally unrelated
chemotherapeutic agents. One of the most common MDR
mechanisms seen in various cancer types is related to the
expression of phosphoglycoprotein multidrug resistance protein
1 (MRP1), part of the ATP-binding cassette. High MRP1
expression has been correlated with reduced tumor responses
to many chemotherapeutic agents, including 5-fluorouracil (5-
FU), along with reduced overall survival times. In order to
address this issue, a study has developed a bio-responsive
hydrogel-nanoprobe comprised of a 5-FU-intercalated DNA
hairpin. This nanoprobe was designed to locally detect and
bind to a complementary MRP1 target sequence within the
TME, resulting in MRP1 silencing and inhibition of protein
expression. Binding of the DNA hairpin to the MRP1 sequence
also caused a conformational change to the nanoprobe, which
resulted in release of 5-FU. A 5-FU resistant breast cancer
murine xenograft model was used to evaluate the ability of
these nanoprobes to detect and overcome MDR. In vivo imaging
was performed for 14 days following the implantation of a
hydrogel disc loaded with nanoparticles into a xenografted
tumor. Luciferase expression was utilized to assess tumor
inhibition, while FITC fluorescence emission could identify
nanoprobes before and after hybridization to MRP1 mRNA.
Results indicated that, despite 5-FU resistance, more than 90%
tumor reduction was achieved following 80% MRP1 silencing.
The authors suggested that this approach could not only be used
to reverse 5-FU resistance, but that it could also be used to
reverse resistance to other chemotherapeutic agents and improve
treatment responses (118).
As opposed to targeting specific resistance mechanisms, other
studies have investigated ways in which the cytotoxicity of
chemotherapeutic agents can be enhanced. A novel solution to
this is through the use of implantable O2-generating depots;
these are designed to improve DOX cytotoxicity by promoting
ROS production through their ability to increase intra-tumoral
O2 concentrations, without affecting systemic levels. Calcium
peroxide (CaO2) alginate microencapsulated pellets have been
developed to react with interstitial fluid, forming calcium
hydroxide [Ca(OH)2] and hydrogen peroxide (H2O2); it is this
H2O2 which then decomposes to release O2. These pellets
have been shown to successfully reduce the hypoxic TME of
Hep3B xenograft tumors and increase the chemotherapeutic
effect of DOX following their implantation into peri-tumoral
tissue. The results from this study demonstrated the feasibility
of using this O2-generating system to locally enhance the
cytotoxic effects of DOX and overcome hypoxia-induced DOX
resistance (53).
Precision Medicine in Veterinary Clinics
Although veterinary precision medicine has yet to be
incorporated into routine clinical practices, there are
encouraging results from pre-clinical and clinical research
studies that provide examples of how it could be used in the
treatment of veterinary patients.
The development of the first canine-specific anti-cancer
drug, toceranib (PalladiaTM), is the current closest example
of veterinary precision medicine routinely used in the clinics.
Toceranib is a novel multi-receptor tyrosine kinase inhibitor
(119). Following pre-clinical studies demonstrating its anti-
proliferative (in vitro cell line models) and anti-angiogenic
activity (in vivo murine xenograft models), phase I trials were
undertaken (120). These trials were conducted in dogs diagnosed
with various tumor types; all patients had a guarded prognosis
as they had either failed standard treatment regimens or there
was no available therapeutic alternative. Results from this trial
and subsequent studies showed toceranib had the greatest tumor
response rates in mast cell tumors (MCT) (121). Toceranib
subsequently gained clinical approval for the treatment of grade
II and III cutaneous MCT. Although this drug was not developed
as part of a precision medicine approach, further investigation
of its mode of action demonstrated that MCT with a specific c-
KIT mutation had better response rates compared to those that
had no mutation (60 vs. 31% response). This c-KIT mutation
was identified as an internal tandem duplication that alters KIT
expression and causes constitutive receptor phosphorylation.
Unlike clinically-approved kinase inhibitors in human medicine,
the approval granted for toceranib did not stipulate its use solely
forMCTwith specific c-KITmutations largely because some dogs
without mutations still responded to treatment. The situation
is also complicated by the issue that there is no clinically-
approved canine genetic test for c-KIT mutations. Therefore,
while toceranib is the closest, evidence-based, precision medicine
approach in veterinary medicine, it currently fails to meet
important considerations in which human-targeted therapies are
based (122).
The use of circulating tumor cells (CTC) and transcriptomics
to provide precision veterinary medicine through the
identification of prognostic, predictive or treatment response
information has also been investigated in multiple studies.
CTC from canine mammary tumors have been shown to
correlate with metastatic disease development and provide
prognostic information that can be used to determine more
aggressive treatment regimens for high-risk patients (123).
Similar approaches have used transcriptomics to generate
prognostic mRNA signatures from canine mammary tumors and
lymphomas. These results demonstrated that the transcriptome
could indicate malignancy and metastatic potential, which again
could be used to identify high-risk patients requiring treatment
intensification (124–127). Canine lymphoma mRNA expression
signatures have also been associated with grade, immuno-
phenotype and therapeutic response. The authors of this study
successfully developed a real-time PCR-based test which they
suggested could be easily adopted for use in clinical cases
(128). A further exciting canine lymphoma study investigated
the assessment of minimal residual disease and response to
treatment (129). To monitor the response to chemotherapy, this
study used a real-time PCR assay to detect immunoglobulin
heavy chain gene fragment sequences in the blood of dogs
diagnosed with high-grade B-cell lymphoma. Results showed
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that the assay could predict the 25 week progression-free survival
from as early as the 11th week of treatment. Translated into
the clinics, these results would enable clinicians to identify
non-responding patients early in their treatment; these patients
could either be transferred onto a different treatment protocol or,
at the very least, be spared the side effects and costs of continuing
an ineffective chemotherapy regimen.
Another study has recently reported the use of a cross-species
personalized medicine approach to identify new therapies for a
dog diagnosed with multiple leiomyosarcomas. This study used
tissue obtained from an excisional biopsy from 1 of the tumors
to establish patient-derived xenograft (PDX) tumors. Using PDX
samples, an in vitro cell line was subsequently established that
was used for high-throughput drug screening. This in vitro work
identified proteasome inhibitors as a potential therapy, which
was then validated using the PDX model. Genomic profiling
of mutations in the original tumors, PDX tumors and cell line
was also performed. While these investigations were taking
place, treatment with toceranib began. After 6 months, disease
progression and local recurrence were detected; the dog was then
treated with the proteasomal inhibitor bortezomib. Although an
initial response was seen, tumor growth began again 6 weeks
after the start of treatment and the dog was euthanized. While
this study demonstrated that drug screening can be performed
on patient-derived samples, the time scale that this occurred
over was approximately 1 year, by which time that patient had
developed metastatic disease and local recurrence. The major
issue with this study is that these metastatic lesions may not
have had the same oncogenic drivers as the original tumor, and
therefore the use of bortezomib may not have been appropriate.
This dog also had 6 original tumors, but cell lines and PDX
tumors were only made from 1; tumor heterogeneity between
the tumors should also have been evaluated. Although the
study demonstrated what can be achieved through using patient
derived samples, the technique is impractical in terms of expense
and the time required to complete the work. These types of
studies can only really be effective if treatment strategies can be
individualized for the patient in order to treat the primary disease
at the time of diagnosis (130).
In contrast to the traditional forms of cancer therapy such
as surgery, radiotherapy and chemotherapy, research has shown
the potential benefits of using immunotherapy in a variety of
cancer types. Studies have investigated whether personalized
immunotherapy can be achieved through the production of
autologous therapeutic anti-tumor vaccines using hydroxyapatite
(HA). HA is an appealing compound for this application, as it
not only attracts antigen-presenting cells, but also presents tumor
antigens to immune cells. Studies have shown that cell membrane
and heat shock proteins extracted from tumor tissue can be
combined with HA to produce a personalized vaccine. Using
this approach, a clinical trial demonstrated that 15% of patients
gained a partial response, while 25% obtained stable disease
following vaccination. The authors suggested that the vaccine
stimulated a T-cell response and that personalized vaccines using
HA combined with self-antigens were safe to use in patients
(131). This approach has subsequently been investigated in dogs
diagnosed with diffuse large B-cell lymphomas (DLBCL) (132).
Results from this clinical trial demonstrated that dogs which
received chemo-immunotherapy had longer progression-free
and lymphoma-specific survival times compared with dogs
that received only chemotherapy. These results suggested that
the personalized vaccine was safe in dogs and could be used
to improve treatment outcomes in dogs with DLBCL. The
authors proposed that this novel therapeutic strategy should be
investigated in human patients diagnosed with DLBCL.
Other studies have shown that immunotherapies using
chimeric antigen receptor (CAR) T cells may have value in
treating human patients with B cell neoplasia; the FDA approved
the use of CD19 CART cells for treating refractory/relapsed acute
lymphoblastic leukemia and DLBCL (133). In line with these
human studies, a recent first-in-species pilot trial investigated
the use of CAR T cells in canine DLBCL patients. Using blood
samples obtained from dogs diagnosed with DLBCL, CD20
CAR T cells were produced ex vivo using lentivectors, as had
been previously done to manufacture human CAR T cells.
Results showed that canine CAR T cells could be detected in
blood samples post-infusion, and that these cells were antigen-
specific, resulting in removal of CD20+ target cells. Survival
times also correlated with ex vivo CD20 CAR T cell expansion.
Unfortunately, the induction of canine anti-mouse antibodies
in the dogs resulted in CAR T cell loss. Furthermore, targeting
CD20+ cells eventually resulted in antigen escape and the
emergence of CD20− disease. However, the study was able to
show the successful lentivector production of functional canine
CAR T cells, while also demonstrating that the challenges of
effective CAR T cell therapy in animals were comparable to those
seen in humans trials (134).
Osteosarcoma is another human and canine tumor type
that may benefit from immunotherapies. Results from both
canine (135–137) and human (138, 139) studies indicate
that osteosarcoma patients which develop a surgical infection
following limb sparing surgery have improved survival times.
Although the immune mechanisms that lead to higher survival
rates after infection are not yet clear these results suggest
an immunogenic component to osteosarcoma pathogenesis.
Studies using a mouse model of chronic bacterial osteomyelitis
suggest that the innate immune system may be involved in the
suppression of osteosarcoma growth (140). Immune modulation
has produced positive effects on patient outcome in both
dogs and humans; further studies are currently underway to
ascertain the most effective immunotherapy or combination of
immunotherapies that will lead to additional improvements in
clinical response. With a better understanding of the methods
required to redirect the immune system toward osteosarcoma,
there is now ample opportunity to change the therapeutic
landscape and improve osteosarcoma treatment in both humans
and dogs (141, 142).
Other veterinary research projects have characterized the
genotypes of several canine cancers including hemangiosarcoma
(143), melanoma (144), and osteosarcoma (145), with the aim
of identifying potential “actionable” targets. Although somatic
mutations in these cancer types (in genes including TP53,
PIK3CA, NRAS, PTEN, and BRAF) have similarities to those
oncogenic mutations found in human cancers, veterinary clinical
trials still need to be performed to confirm if they respond to
targeted inhibition. Clinical trials that merge information gained
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from sequencing individual canine tumors with survival data
after targeted treatment could in the future influence the selection
of treatment regimens for canine cancer patients. These types
of trials have the potential to provide evidence to clinicians
and clients that cancer genome sequencing for their pets could
lead to improved outcomes though the adoption of a precision
medicine approach.
Current Issues Limiting the Use of
Precision Medicine
The translation of precision medicine approaches into accepted
healthcare practices and policies has undoubtedly lagged behind
the significant discoveries made through pre-clinical research.
It is to be expected that, as with all novel innovations, it
will take years to achieve this successful translation. Precision
medicine is complicated by the fact that it not only represents
a significant paradigm shift in how we treat cancer patients,
but is also associated with complex legal, financial, social and
ethical issues. The National Academy of Medicine outlined
multiple challenges faced by the Precision Medicine Initiative,
including the development of infrastructures that enable data
sharing and easy access to extensive, highly-integrated clinical
data sets. They also highlighted the absolute need for evidence
that precision medicine can actually improve patient outcomes
(146). To date, only a few clinical trials have assessed the
adoption of a precision medicine approach for the treatment
of cancer patients. The first of such precision medicine clinical
trials involved refractory metastatic cancer patients. The results
demonstrated that longer progression-free intervals could be
achieved in patients that underwent molecular cancer profiling
to guide their treatment (147). Unfortunately, other studies
have suggested that there is limited evidence to support the
use of genomic tests in healthcare practices (148, 149). The
economic feasibility of adopting precision medicine policies is
another significant challenge, as its successful implementation
will ultimately depend on whether patients and healthcare
providers are willing to pay for them. Currently, there is limited
evidence that precision medicine provides sufficient cost-benefit
advantages over standard treatment protocols. Some researchers
even suggest that precision medicine could be a distraction from
low-cost and effective population-wide interventions and that
policies which focus on public health and prevention should be
prioritized (150). Finally, precision medicine raises important
questions regarding patient trust, including issues related to who
actually owns the genetic data and how it can be securely stored.
To address some of these issues, centers such as The
Personalized Medicine Coalition in the USA and The Center
for Personalized Medicine in the UK have been established
(151). Other on-going initiatives include the Clinical Sequencing
Evidence-Generating Research center and the Implementing
GeNomics In practice (IGNITE) project, which aim to support
the integration of genome sequencing into healthcare practices
(8). In veterinary medicine, following sequencing of the canine
genome, the Canine Comparative Oncology and Genomics
Consortium (CCOGC) was formed in 2004. This programme
aims to generate an extensive archive (from 3,000 dogs) of
clinical samples (neoplastic and non-neoplastic tissue, whole
blood, plasma, serum and urine) from lymphoma, osteosarcoma,
hemangiosarcoma, mast cell tumor, pulmonary, melanoma and
soft tissue sarcomas. In 2013, the CCOGC biorepository was
opened to the research community with the aim of improving
the molecular characterization of canine cancers in order to help
provide precision veterinary healthcare (152).
The challenges that limit the successful integration of
precision medicine in human healthcare practices are equally
applicable to veterinary medicine. As public awareness of
the potential human benefits of precision medicine increases,
veterinary clients will start to ask whether similar, precision-
guided approaches can benefit their pets. This will become even
more evident if pet owners themselves have received treatment
as part of a precision medicine approach. In the future, the
veterinary profession will need to adapt to the changes that are
associated with precision medicine. Significant investment will
be required to encourage openness for sharing research results
and clinical data. Clinicians will also need to be trained in
the use of molecular-based diagnostic assays and in performing
high quality clinical trials using appropriately identified targeted
treatments. Underpinning these ideas will ultimately require
training and educational programmes for veterinary clinicians
and veterinary healthcare professionals in subject areas such
as tumor heterogeneity, genomic medicine, bioinformatics and
targeted therapeutics, all of which are key components within
human precision medicine.
CONCLUSION
Precision medicine has the potential to transform the way
in which we treat human and veterinary cancer patients.
Ongoing basic and clinical research is continuing to improve
our understanding of tumor heterogeneity and is providing new
information on how it influences disease prognosis and treatment
responses. The challenge lies in the successful translation of
these exciting results into novel diagnostic and therapeutic
strategies for clinical use. Multidisciplinary projects that take
on a one-health view to precision medicine, involving human
and veterinary clinicians, engineers and chemists, are likely to
become more important in the future if we are to ultimately
advance the field of precision medicine to a stage where it can be
fully integrated into clinical practices. Our review has highlighted
this with studies investigating the TME and with research using
novel implantable medical devices. Although precision medicine
is still largely focused on human healthcare, we have shown
that there have been exciting clinical research studies in the
field of veterinary precision medicine, with promising results.
These types of studies are likely to increase as more researchers
realize that many of the cancers seen in veterinary patients share
significant similarities with human equivalent cancers, including
the molecular mechanisms of disease pathogenesis and the TME.
It is these types of similarities that may prove to be clinically
relevant and therapeutically actionable for both human and
veterinary patients. Adopting a one-health approach, in which
researchers and clinicians from both human and veterinary
fields collaborate, will ultimately aid translational studies
and improve the integration of precision medicine initiatives
into healthcare practices for both human and veterinary
cancer patients.
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